Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brivaracetam add-on therapy in pediatric partial-onset epilepsy (PK, safety, efficacy)
ChiCTR2500105087Phase 3Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of brivaracetam in Focal Onset Epilepsy (3 arms), sponsored by Peking University First Hospital. Primary endpoints: Incidence of treatment-emergent adverse events (TEAEs), Incidence of study-drug-related serious adverse events (SAEs) and 2 more. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
brivaracetam
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on ChiCTR2500105087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105087.